Accentuating the caveat emptor perspective with critical commentary on financial disclosure. I adopt a skeptical persona and look for chinks in the teflon coating of financial disclosure. My job is to identify financial warts. Perhaps a Black Swan. Disclosure: I do not hold positions in stocks mentioned for three trading days before or after blog post.
Tuesday, February 14, 2006
Nymox Pharmaceuticals (NASDAQ:NYMY) touts its own paid for research!
Nymox Pharmaceuticals (Nasdaq:NYMY) recently issued a press release touting they three analysts have issued buy recommendations. Nymox neglects to point out the three analyst firms are “paid for” and therefore are not what you might expect from a third party. The issue of paid for research continues to vex the investment world. By the way Nymox some of the reports are really old anyway and its time to update them.